{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:20Z","timestamp":1793146400293,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Xiangyang central Hospital","award":["2012050689"],"award-info":[{"award-number":["2012050689"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12094-017-1786-z","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T05:01:56Z","timestamp":1509339716000},"page":"761-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma"],"prefix":"10.1007","volume":"20","author":[{"given":"J.","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2237-9547","authenticated-orcid":false,"given":"D.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"1786_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.05.006","author":"AT Beksac","year":"2017","unstructured":"Beksac AT, Paulucci DJ, Blum KA, Yadav SS, Sfakianos JP, Badani KK. Heterogeneity in renal cell carcinoma. Urolo Oncol. 2017;. \n                        https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.006\n                        \n                    .","journal-title":"Urolo Oncol."},{"issue":"8","key":"1786_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrneph.2017.82","volume":"13","author":"EM Posadas","year":"2017","unstructured":"Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13(8):496\u2013511. \n                        https:\/\/doi.org\/10.1038\/nrneph.2017.82\n                        \n                    .","journal-title":"Nat Rev Nephrol."},{"issue":"14","key":"1786_CR3","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-07-0752","volume":"67","author":"O Larsson","year":"2007","unstructured":"Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K, et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 2007;67(14):6814\u201324. \n                        https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0752\n                        \n                    .","journal-title":"Cancer Res"},{"issue":"16","key":"1786_CR4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926\u201345. \n                        https:\/\/doi.org\/10.1101\/gad.1212704\n                        \n                    .","journal-title":"Genes Dev"},{"issue":"4","key":"1786_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd4505","volume":"14","author":"M Bhat","year":"2015","unstructured":"Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14(4):261\u201378. \n                        https:\/\/doi.org\/10.1038\/nrd4505\n                        \n                    .","journal-title":"Nat Rev Drug Discov."},{"issue":"2","key":"1786_CR6","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1371\/journal.pone.0000242","volume":"2","author":"Y Mamane","year":"2007","unstructured":"Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE. 2007;2(2):e242. \n                        https:\/\/doi.org\/10.1371\/journal.pone.0000242\n                        \n                    .","journal-title":"PLoS ONE"},{"issue":"52","key":"1786_CR7","doi-asserted-by":"publisher","first-page":"18105","DOI":"10.1073\/pnas.0406927102","volume":"101","author":"A Kentsis","year":"2004","unstructured":"Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA. 2004;101(52):18105\u201310. \n                        https:\/\/doi.org\/10.1073\/pnas.0406927102\n                        \n                    .","journal-title":"Proc Natl Acad Sci USA."},{"issue":"9","key":"1786_CR8","first-page":"2838","volume":"5","author":"L Campbell","year":"2015","unstructured":"Campbell L, Jasani B, Griffiths DF, Gumbleton M. Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. Am J Cancer Res. 2015;5(9):2838\u201348.","journal-title":"Am J Cancer Res."},{"issue":"2","key":"1786_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","volume":"80","author":"S Crotty","year":"2002","unstructured":"Crotty S, Cameron C, Andino R. Ribavirin\u2019s antiviral mechanism of action: lethal mutagenesis? J Mol Med. 2002;80(2):86\u201395. \n                        https:\/\/doi.org\/10.1007\/s00109-001-0308-0\n                        \n                    .","journal-title":"J Mol Med"},{"issue":"4","key":"1786_CR10","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.bbrc.2016.12.025","volume":"482","author":"D Dai","year":"2017","unstructured":"Dai D, Chen H, Tang J, Tang Y. Inhibition of mTOR\/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma. Biochem Biophys Res Commun. 2017;482(4):1259\u201364. \n                        https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.025\n                        \n                    .","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"1786_CR11","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1182\/blood-2003-07-2193","volume":"103","author":"MG Kharas","year":"2004","unstructured":"Kharas MG, Deane JA, Wong S, O\u2019Bosky KR, Rosenberg N, Witte ON, et al. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 2004;103(11):4268\u201375. \n                        https:\/\/doi.org\/10.1182\/blood-2003-07-2193\n                        \n                    .","journal-title":"Blood"},{"issue":"9","key":"1786_CR12","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-10-2334","volume":"17","author":"F Pettersson","year":"2011","unstructured":"Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res. 2011;17(9):2874\u201384. \n                        https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2334\n                        \n                    .","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1786_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12943-016-0565-8","volume":"15","author":"KK Brodaczewska","year":"2016","unstructured":"Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Choosing the right cell line for renal cell cancer research. Mol Cancer. 2016;15(1):83. \n                        https:\/\/doi.org\/10.1186\/s12943-016-0565-8\n                        \n                    .","journal-title":"Mol Cancer."},{"issue":"3","key":"1786_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.163","volume":"375","author":"K Tan","year":"2008","unstructured":"Tan K, Culjkovic B, Amri A, Borden KL. Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun. 2008;375(3):341\u20135. \n                        https:\/\/doi.org\/10.1016\/j.bbrc.2008.07.163\n                        \n                    .","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"1786_CR15","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1101\/gad.1604407","volume":"21","author":"HG Wendel","year":"2007","unstructured":"Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232\u20137. \n                        https:\/\/doi.org\/10.1101\/gad.1604407\n                        \n                    .","journal-title":"Genes Dev"},{"issue":"7","key":"1786_CR16","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","volume":"11","author":"LM Minasian","year":"1993","unstructured":"Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11(7):1368\u201375. \n                        https:\/\/doi.org\/10.1200\/JCO.1993.11.7.1368\n                        \n                    .","journal-title":"J Clin Oncol"},{"key":"1786_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2016.06.005","author":"M Grzmil","year":"2016","unstructured":"Grzmil M, Seebacher J, Hess D, Behe M, Schibli R, Moncayo G, et al. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. Cell Signal. 2016;. \n                        https:\/\/doi.org\/10.1016\/j.cellsig.2016.06.005\n                        \n                    .","journal-title":"Cell Signal"},{"key":"1786_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.015","author":"A Bindayi","year":"2017","unstructured":"Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urolo Oncol. 2017;. \n                        https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.015\n                        \n                    .","journal-title":"Urolo Oncol."},{"issue":"2","key":"1786_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","volume":"114","author":"S Assouline","year":"2009","unstructured":"Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009;114(2):257\u201360. \n                        https:\/\/doi.org\/10.1182\/blood-2009-02-205153\n                        \n                    .","journal-title":"Blood"},{"issue":"2","key":"1786_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4254\/wjh.v8.i2.123","volume":"8","author":"V Loustaud-Ratti","year":"2016","unstructured":"Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, et al. Ribavirin: past, present and future. World J Hepatol. 2016;8(2):123\u201330. \n                        https:\/\/doi.org\/10.4254\/wjh.v8.i2.123\n                        \n                    .","journal-title":"World J Hepatol."},{"issue":"8","key":"1786_CR21","doi-asserted-by":"publisher","first-page":"e0136746","DOI":"10.1371\/journal.pone.0136746","volume":"10","author":"F Shi","year":"2015","unstructured":"Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, et al. Ribavirin inhibits the activity of mTOR\/eIF4E, ERK\/Mnk1\/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph\u00a0+\u00a0leukemia. PLoS ONE. 2015;10(8):e0136746. \n                        https:\/\/doi.org\/10.1371\/journal.pone.0136746\n                        \n                    .","journal-title":"PLoS ONE"},{"issue":"7","key":"1786_CR22","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/leu.2011.57","volume":"25","author":"BC Kraljacic","year":"2011","unstructured":"Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 2011;25(7):1197\u2013200. \n                        https:\/\/doi.org\/10.1038\/leu.2011.57\n                        \n                    .","journal-title":"Leukemia"},{"issue":"12","key":"1786_CR23","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1261\/rna.2238705","volume":"11","author":"A Kentsis","year":"2005","unstructured":"Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, et al. Further evidence that ribavirin interacts with eIF4E. RNA. 2005;11(12):1762\u20136. \n                        https:\/\/doi.org\/10.1261\/rna.2238705\n                        \n                    .","journal-title":"RNA"},{"issue":"5","key":"1786_CR24","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3892\/or.2015.3816","volume":"33","author":"E Cruz-Hernandez De la","year":"2015","unstructured":"De la Cruz-Hernandez E, Medina-Franco JL, Trujillo J, Chavez-Blanco A, Dominguez-Gomez G, Perez-Cardenas E, et al. Ribavirin as a tri-targeted antitumor repositioned drug. Oncol Rep. 2015;33(5):2384\u201392. \n                        https:\/\/doi.org\/10.3892\/or.2015.3816\n                        \n                    .","journal-title":"Oncol Rep"},{"issue":"3","key":"1786_CR25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/157488411797189424","volume":"6","author":"TK Choueiri","year":"2011","unstructured":"Choueiri TK. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective. Curr Clin Pharmacol. 2011;6(3):164\u20138.","journal-title":"Curr Clin Pharmacol."},{"issue":"3","key":"1786_CR26","first-page":"1203","volume":"9","author":"H Xu","year":"2017","unstructured":"Xu H, Wang Z, Xu L, Mo G, Duan G, Wang Y, et al. Targeting the eIF4E\/beta-catenin axis sensitizes cervical carcinoma squamous cells to chemotherapy. Am J Trans Res. 2017;9(3):1203\u201312.","journal-title":"Am J Trans Res."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1786-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1786-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T03:13:28Z","timestamp":1525835608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1786-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1786-z","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]}}}